Following a limited submission
AWMSG advice |
|||
Status: Recommended with restrictions | |||
Bortezomib (Velcade®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib (Velcade®) should be restricted for use in combination with dexamethasone. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised. Bortezomib (Velcade®) is not recommended for use within NHS Wales in combination with pegylated liposomal doxorubicin. |
|||
|
|||
Medicine details |
|||
Medicine name | bortezomib (Velcade®) | ||
Formulation | 3.5 mg powder for solution for injection | ||
Reference number | 1807 | ||
Indication | In combination with pegylated liposomal doxorubicin or dexamethasone for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation |
||
Company | Janssen-Cilag Ltd | ||
BNF chapter | Malignant disease & immunosuppression | ||
Submission type | Limited | ||
Status | Recommended with restrictions | ||
Advice number | 2814 | ||
NMG meeting date | 10/09/2014 | ||
AWMSG meeting date | 08/10/2014 | ||
Ratification by Welsh Government | 30/10/2014 | ||
Date of issue | 31/10/2014 | ||
Date of last review | 20/12/2017 | ||
Commercial arrangement | PAS |